220514-28-3

Basic information

• Product Name: 5-BROMO-2-METHYL-3-NITROPHENYL METHYLCARBOXYLATE
• Synonyms: 5-BROMO-2-METHYL-3-NITROPHENYL METHYLCARBOXYLATE;Methyl 5-Bromo-2-methyl-3-nitrobenzoate;2-Methyl-5-BroMo-3-nitrobenzoicacidMethylester;5-broMo-2-Methyl-3-nitrophenyl acetate;Benzoic acid, 5-broMo-2-Methyl-3-nitro-, Methyl ester
• CAS NO: 220514-28-3
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.07
• EINECS: 1533716-785-6
• Mol File: 220514-28-3.mol
• Article Data: 25

Chemical Properties

• Melting Point: 51.0 to 55.0 °C
• Boiling Point: 329.563 °C at 760 mmHg
• Flash Point: 153.114 °C
• Appearance: /
• Density: 1.597 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-BROMO-2-METHYL-3-NITROPHENYL METHYLCARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-METHYL-3-NITROPHENYL METHYLCARBOXYLATE(220514-28-3)
• EPA Substance Registry System: 5-BROMO-2-METHYL-3-NITROPHENYL METHYLCARBOXYLATE(220514-28-3)

Safety Data

• Hazardous Substances Data: 220514-28-3(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-methyl-3-nitrophenyl methylcarboxylate is a chemical compound with a molecular formula C9H8BrNO5. It is a yellow solid with a molecular weight of 281.07 g/mol. 5-BROMO-2-METHYL-3-NITROPHENYL METHYLCARBOXYLATE is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is also known for its potential application in organic synthesis and as a reagent in chemical reactions. The presence of a methylcarboxylate group makes it a versatile intermediate that can be used in various synthetic processes to create new compounds with different properties and applications. Additionally, its nitro and bromo substituents provide unique reactivity and functionality for further chemical modifications.

InChI:InChI=1/C9H8BrNO4/c1-5-7(9(12)15-2)3-6(10)4-8(5)11(13)14/h3-4H,1-2H3

Upstream product

• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 118-90-1 ortho-methylbenzoic acid 
• 79669-50-4 methyl 2-methyl-5-bromobenzoate 
• 67-56-1 methanol 
• 107650-20-4 5-bromo-2-methyl-3-nitro-benzoic acid 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1005499-49-9 methyl 5-nitro-3'-(ethylsulfonyl)-4-methylbiphenyl-3-carboxylate 
• 885518-49-0 methyl 6-bromo-1H-indazole-4-carboxylate 
• 1346702-54-2 6-bromo-1-(1-methylethyl)-1H-indazole-4-carboxylic acid 
• 1346702-52-0 methyl 6-bromo-1-(1-methylethyl)-1H-indazole-4-carboxylate 
• 1396772-45-4 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(morpholinomethyl)phenyl)-1H-indazole-4-carboxamide 
• 1396772-66-9 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-(methylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396772-71-6 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-(dimethylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396772-75-0 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(3-(methylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1000342-11-9 2-methyl-3-amino-5-bromobenzoic acid methyl ester 
• 1346597-55-4 methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate 
• 1396780-39-4 methyl 1-cyclopentyl-6-(3-hydroxyphenyl)-1H-indazole-4-carboxylate 
• 1396780-41-8 methyl 1-cyclopentyl-6-(3-(3-hydroxypropoxy)phenyl)-1H-indazole-4-carboxylate 
• 1396780-46-3 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-hydroxypropoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396780-42-9 C₂₂H₂₄N₂O₄ 

Relevant articles and documents

SKLB1039 Compound as well as preparation method and application thereof

The invention belongs to the technical field of preparation of new compounds, and particularly relates SKLB1039 compound as well as a preparation method and application thereof. The 2 -methyl -3 -nitrobenzoic acid is taken as an initial raw material and is brominated. Esterification, reduction, reductive amination and hydrolysis synthesis 5 - bromo -2 - methyl -3 - (N - ethyl, N - (tetrahydropyran -4 - yl)) aminobenzoic acid. The cyclohexanone serving as a raw material is subjected to catalytic hydrogenation reduction of carbonyl α, acetyl cyclohexanone and cyanopyridone to synthesize 4 - aminomethyl -1 - methyl -5, 6, 7, 8 - tetrahydroisoquinoline -3 (2H) - ketone. Coupling the two to an amide is followed by catalytic coupling with an aryl sheet to give SKLB1039 a compound. SKLB1039 Large-scale preparation technology is provided, operation is easy, the post-treatment purification process is simple, the total route yield is improved, raw materials are easy to purchase, the price is low, and the production cost is greatly reduced.

Synthesis and evaluation of a novel series of 6-bromo-1-cyclopentyl-1H-indazole-4-carboxylic acid-substituted amide derivatives as anticancer, antiangiogenic, and antioxidant agents

A series of novel indazole derivatives has been synthesized and evaluated for anticancer, antiangiogenic, and antioxidant activities. The capability of the synthesized compounds 11a–x to hinder the viability of three human cancer cells lines, HEP3BPN 11 (liver), MDA 453 (breast), and HL 60 (leukemia), were assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Among the compounds 11a–x screened, 11c and 11d showed the higher inhibitory activity on the viability of HEP3BPN 11 (liver), when compared with the standard methotrexate. These compounds were further tested to evaluate their potential to inhibit the proangiogenic cytokines associated with tumor development. Compound 11c was found to be a potent antiangiogenic agent against TNFα, VEGF, and EGF, whereas 11d showed potent antiangiogenic activity against TNFα, VEGF, IGF1, TGFb, and leptin inhibition. All the compounds 11a–x were screened for their antioxidant activities using 2,2-diphenyl-1-picryl hydrazine (DPPH), hydroxyl (OH), and superoxide radical (SOR) scavenging activity. Compounds 11n, 11p, 11q, and 11v have shown significant OH radical scavenging activities, also compounds 11c, 11h, and 11k were found to have a DPPH radical scavenging activity and compounds 11a and 11m exhibited better SOR scavenging activity when compared with the reference compound ascorbic acid. In silico molecular docking analysis revealed important structural insights behind observed anti TNFα effect by present indazole compounds.

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell pr